Download PDF
Semin intervent Radiol 2019; 36(03): 213-220
DOI: 10.1055/s-0039-1693980
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Irreversible Electroporation of the Pancreas

Gabriel Chan
1   Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore
,
Uei Pua
1   Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore
2   Yong Loo Lin School of Medicine, National University of Singapore, Singapore
› Author Affiliations
Further Information

Publication History

Publication Date:
19 August 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Irreversible electroporation (IRE) is a relatively recent method of ablation. In contrast to many ablation devices that use thermal methods to induce cell death, IRE employs the use of an electric field to cause irreversible permeability of the cell membrane, thus inducing apoptosis. Since its use in the pancreas was first described in 2012, IRE has become established as part of the armamentarium of ablation devices currently available. The crucial advantage of IRE compared with other devices employing thermal ablation is the safety around vital structures such as vessels and ducts. This is especially important in the pancreas due to the close proximity of multiple major vascular structures, biliary ducts, and adjacent gastrointestinal organs. This article will explore the current evidence regarding the use of IRE in the pancreas.

Keywords

interventional radiology - pancreas - ablation - irreversible electroporation
 

  • References

  • 1 Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33 (02) 223-231
    CrossrefPubMedGoogle Scholar
  • 2 Martin II RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 2012; 215 (03) 361-369
    CrossrefPubMedGoogle Scholar
  • 3 D'Onofrio M, Barbi E, Girelli R. , et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 2010; 16 (28) 3478-3483
    CrossrefPubMedGoogle Scholar
  • 4 Martin II RC, Durham AN, Besselink MG. , et al. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. J Surg Oncol 2016; 114 (07) 865-871
    CrossrefPubMedGoogle Scholar
  • 5 Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 2010; 110 (05) 1305-1309
    CrossrefPubMedGoogle Scholar
  • 6 Nielsen K, Scheffer HJ, Vieveen JM. , et al. Anaesthetic management during open and percutaneous irreversible electroporation. Br J Anaesth 2014; 113 (06) 985-992
    CrossrefPubMedGoogle Scholar
  • 7 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 8 Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol 2017; 52 (11) 1165-1171
    CrossrefPubMedGoogle Scholar
  • 9 Martin II RC, Kwon D, Chalikonda S. , et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015; 262 (03) 486-494 , discussion 492–494
    CrossrefPubMedGoogle Scholar
  • 10 Holland MM, Bhutiani N, Kruse EJ. , et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB (Oxford) 2019 doi: 10.1016/j.hpb.2018.12.004. [Epub ahead of print]
    PubMedGoogle Scholar
  • 11 Kwon D, McFarland K, Velanovich V, Martin II RC. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery 2014; 156 (04) 910-920
    CrossrefPubMedGoogle Scholar
  • 12 Narayanan G, Hosein PJ, Beulaygue IC. , et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 2017; 28 (03) 342-348
    CrossrefPubMedGoogle Scholar
  • 13 Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson BM. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol 2016; 42 (09) 1401-1406
    CrossrefPubMedGoogle Scholar
  • 14 Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7 (04) e1000267
    CrossrefPubMedGoogle Scholar
  • 15 Narayanan G, Hosein PJ, Arora G. , et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012; 23 (12) 1613-1621
    CrossrefPubMedGoogle Scholar
  • 16 Kluger MD, Epelboym I, Schrope BA. , et al. Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol 2016; 23 (05) 1736-1743
    CrossrefPubMedGoogle Scholar
  • 17 Zhang Y, Shi J, Zeng J. , et al. Percutaneous irreversible electroporation for ablation of locally advanced pancreatic cancer: experience from a Chinese institution. Pancreas 2017; 46 (02) e12-e14
    PubMedGoogle Scholar
  • 18 Lambert L, Horejs J, Krska Z. , et al. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma 2016; 63 (02) 269-273
    PubMedGoogle Scholar
  • 19 Belfiore MP, Ronza FM, Romano F. , et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience. Int J Surg 2015; 21 (Suppl. 01) S34-S39
    CrossrefPubMedGoogle Scholar
  • 20 Martin II RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20 (Suppl. 03) S443-S449
    CrossrefPubMedGoogle Scholar
  • 21 Fritz S, Sommer CM, Vollherbst D. , et al. Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 2015; 44 (05) 791-798
    CrossrefPubMedGoogle Scholar
  • 22 Wimmer T, Srimathveeravalli G, Gutta N. , et al. Comparison of simulation-based treatment planning with imaging and pathology outcomes for percutaneous CT-guided irreversible electroporation of the porcine pancreas: a pilot study. J Vasc Interv Radiol 2013; 24 (11) 1709-1718
    CrossrefPubMedGoogle Scholar
  • 23 Akinwande O, Ahmad SS, Van Meter T, Schulz B, Martin RC. CT findings of patients treated with irreversible electroporation for locally advanced pancreatic cancer. J Oncol 2015; 2015: 680319
    PubMedGoogle Scholar
  • 24 Schulz B, Ou J, Van Meter T, Martin RC. Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Abdom Radiol (NY) 2016; 41 (11) 2142-2149
    CrossrefPubMedGoogle Scholar
  • 25 Gonzalez-Beicos A, Venkat S, Songrug T. , et al. Irreversible electroporation of hepatic and pancreatic malignancies: radiologic-pathologic correlation. Tech Vasc Interv Radiol 2015; 18 (03) 176-182
    CrossrefPubMedGoogle Scholar
  • 26 Tarantino L, Nasto A, Busto G, Iovino V, Fristachi R, Bortone S. Irreversible electroporation of locally advanced solid pseudopapillary carcinoma of the pancreas: a case report. Ann Med Surg (Lond) 2018; 28 (28) 11-15
    PubMedGoogle Scholar
  • 27 Niu L, Li J, Zeng J. , et al. Percutaneous irreversible electroporation for pancreatic VIPoma: a case report. Pancreas 2017; 46 (01) 135-137
    CrossrefPubMedGoogle Scholar
  • 28 Mele C, Brunani A, Damascelli B. , et al. Non-surgical ablative therapies for inoperable benign insulinoma. J Endocrinol Invest 2018; 41 (02) 153-162
    CrossrefPubMedGoogle Scholar
  • 29 Lee JM, Choi HS, Chun HJ. , et al. EUS-guided irreversible electroporation using endoscopic needle-electrode in porcine pancreas. Surg Endosc 2019; 33 (02) 658-662
    CrossrefPubMedGoogle Scholar
  • 30 Tartaglia E, Fabozzi M, Rizzuto A. , et al. Irreversible electroporation for locally advanced pancreatic cancer through a minimally invasive surgery supported by laparoscopic ultrasound. Int J Surg Case Rep 2018; 42: 290-294
    CrossrefPubMedGoogle Scholar